mTOR: Its Critical Role in Metabolic Diseases, Cancer, and the Aging Process
暂无分享,去创建一个
[1] Rui-yuan Jiang,et al. PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer. , 2024, Breast cancer.
[2] A. Salminen. The role of the immunosuppressive PD-1/PD-L1 checkpoint pathway in the aging process and age-related diseases , 2024, Journal of molecular medicine.
[3] A. Vincent-Salomon,et al. The prognosis of patients treated with everolimus for advanced ER‐positive, HER2‐negative breast cancer is driven by molecular features , 2024, The journal of pathology. Clinical research.
[4] Yilin Ren,et al. A Free Amino Acid Diet Alleviates Colorectal Tumorigenesis through Modulating Gut Microbiota and Metabolites , 2024, Nutrients.
[5] P. Nghiemphu,et al. Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma , 2024, Journal of neuro-oncology.
[6] Shuchi Gulati,et al. Belzutifan versus Everolimus in Advanced Kidney Cancer: A Commentary on LITESPARK-005 Trial from ESMO 2023 , 2024, Kidney cancer.
[7] A. Naing,et al. Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors , 2024, Cancer medicine.
[8] F. Janku,et al. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies , 2023, Cancer research communications.
[9] A. Ibrahimi,et al. Virtual docking screening and quantitative structure-activity relationship studies to explore AKT and PI3K inhibitors acting on mTOR in cancers by theoretical biology and medical modeling , 2023, Contemporary oncology.
[10] Ke Zhou,et al. RapaLink-1 outperforms rapamycin in alleviating allogeneic graft rejection by inhibiting the mTORC1-4E-BP1 pathway in mice. , 2023, International immunopharmacology.
[11] R. Costa,et al. MTOR gene variants are associated with severe COVID-19 outcomes: A multicenter study. , 2023, International immunopharmacology.
[12] R. Tonk,et al. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease , 2023, Signal transduction and targeted therapy.
[13] B. García-Pérez,et al. Autophagy as a Target for Non-Immune Intrinsic Functions of Programmed Cell Death-Ligand 1 in Cancer , 2023, International journal of molecular sciences.
[14] Sulaiman K. Marafie,et al. An Overview of the Role of Furin in Type 2 Diabetes , 2023, Cells.
[15] Jun Liu,et al. The causal effect of mTORC1-dependent circulating protein levels on nonalcoholic fatty liver disease: A Mendelian randomization study. , 2023, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[16] G. Sethi,et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer , 2023, Molecular Cancer.
[17] Yao Yang,et al. mTORC2 acts as a gatekeeper for mTORC1 deficiency-mediated impairments in ILC3 development , 2023, Acta Pharmacologica Sinica.
[18] S. Taeb,et al. The mTOR Signaling Pathway Interacts with the ER Stress Response and the Unfolded Protein Response in Cancer. , 2023, Cancer research.
[19] P. Rangamani,et al. Computational modeling of AMPK and mTOR crosstalk in glutamatergic synapse calcium signaling , 2023, bioRxiv.
[20] D. Olive,et al. Major pathways involved in macrophage polarization in cancer , 2022, Frontiers in Immunology.
[21] R. Coppari,et al. Hepatic non-parenchymal S100A9-TLR4-mTORC1 axis normalizes diabetic ketogenesis , 2022, Nature Communications.
[22] Jing Gao,et al. Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy , 2022, Frontiers in Immunology.
[23] Aramati B. M. Reddy,et al. High glutamine suppresses osteogenesis through mTORC1-mediated inhibition of the mTORC2/AKT-473/RUNX2 axis , 2022, Cell death discovery.
[24] T. Sargeant,et al. The mTOR–lysosome axis at the centre of ageing , 2021, FEBS open bio.
[25] Yongshun Chen,et al. Autophagy controls programmed death-ligand 1 expression on cancer cells (Review). , 2021, Biomedical reports.
[26] Yongzhong Hou,et al. Role of autophagy on cancer immune escape , 2021, Cell communication and signaling : CCS.
[27] Oriol Vinyals,et al. Highly accurate protein structure prediction with AlphaFold , 2021, Nature.
[28] I. Park,et al. Inhibition of mTORC1 through ATF4-induced REDD1 and Sestrin2 expression by Metformin , 2021, BMC cancer.
[29] F. Schuit,et al. Loss of Furin in β-Cells Induces an mTORC1-ATF4 Anabolic Pathway That Leads to β-Cell Dysfunction , 2020, Diabetes.
[30] N. Cross,et al. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment , 2020, Frontiers in Immunology.
[31] Jun Yu,et al. Gut microbiome alters functions of mutant p53 to promote tumorigenesis , 2020, Signal Transduction and Targeted Therapy.
[32] David C. Smith,et al. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer , 2020, British Journal of Cancer.
[33] César Martín,et al. Pathophysiology of Type 2 Diabetes Mellitus , 2020, International journal of molecular sciences.
[34] M. Oren,et al. The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic , 2020, Nature.
[35] R. Cao,et al. Phosphorylation of the mRNA cap-binding protein eIF4E and cancer. , 2020, Cellular signalling.
[36] Sulaiman K. Marafie,et al. Palmitic acid-induced lipotoxicity promotes a novel interplay between Akt-mTOR, IRS-1, and FFAR1 signaling in pancreatic β-cells , 2019, Biological Research.
[37] S. Burgess,et al. Impaired ketogenesis and increased acetyl-CoA oxidation promote hyperglycemia in human fatty liver. , 2019, JCI insight.
[38] Jun Yu,et al. Autophagy inhibition enhances PD-L1 expression in gastric cancer , 2019, Journal of Experimental & Clinical Cancer Research.
[39] J. Loor,et al. Methionine and valine activate the mammalian target of rapamycin complex 1 pathway through heterodimeric amino acid taste receptor (TAS1R1/TAS1R3) and intracellular Ca2+ in bovine mammary epithelial cells. , 2018, Journal of dairy science.
[40] G. Shulman,et al. Mechanisms of Insulin Action and Insulin Resistance. , 2018, Physiological reviews.
[41] Mee-Sup Yoon. The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling , 2017, Nutrients.
[42] L. Zheng,et al. Clk1‐regulated aerobic glycolysis is involved in glioma chemoresistance , 2017, Journal of neurochemistry.
[43] D. Sabatini,et al. mTOR Signaling in Growth, Metabolism, and Disease , 2017, Cell.
[44] T. Curiel,et al. Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. , 2016, Cancer research.
[45] Si Ming Man,et al. NLRC3 is an inhibitory sensor of PI3K–mTOR pathways in cancer , 2016, Nature.
[46] K Bhattacharya,et al. PTEN negatively regulates mTORC2 formation and signaling in grade IV glioma via Rictor hyperphosphorylation at Thr1135 and direct the mode of action of an mTORC1/2 inhibitor , 2016, Oncogenesis.
[47] J. Ting,et al. Expression profile of innate immune receptors, NLRs and AIM2, in human colorectal cancer: correlation with cancer stages and inflammasome components , 2015, Oncotarget.
[48] J. Sarkaria,et al. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. , 2015, Neuro-oncology.
[49] T. Asano,et al. A hepatic amino acid/mTOR/S6K-dependent signalling pathway modulates systemic lipid metabolism via neuronal signals , 2015, Nature Communications.
[50] G. Thomas,et al. A liaison between mTOR signaling, ribosome biogenesis and cancer. , 2015, Biochimica et biophysica acta.
[51] G. Poulin,et al. A nuclear role for the respiratory enzyme CLK-1/COQ7 in regulating mitochondrial stress responses and longevity , 2015, Nature Cell Biology.
[52] Seamus J. Martin,et al. Autophagy in malignant transformation and cancer progression , 2015, The EMBO journal.
[53] D. Gu,et al. Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma. , 2015, Cancer letters.
[54] A. Dillin,et al. Tipping the metabolic scales towards increased longevity in mammals , 2015, Nature Cell Biology.
[55] Cheng Fang,et al. Androgen Receptor, EGFR, and BRCA1 as Biomarkers in Triple-Negative Breast Cancer: A Meta-Analysis , 2015, BioMed research international.
[56] N. Chandel. Mitochondria as signaling organelles , 2014, BMC Biology.
[57] R. Schneider,et al. Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer. , 2014, Gynecologic oncology.
[58] C. Rommel,et al. PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.
[59] O. Gavrilova,et al. Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression. , 2013, Cell reports.
[60] L. Partridge,et al. The Hallmarks of Aging , 2013, Cell.
[61] C. Rommel,et al. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia , 2013, Leukemia.
[62] P. Rabinovitch,et al. mTOR is a key modulator of ageing and age-related disease , 2013, Nature.
[63] N. Chandel,et al. Physiological roles of mitochondrial reactive oxygen species. , 2012, Molecular cell.
[64] I. Ray-Coquard,et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] Kira Glover-Cutter,et al. TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO. , 2012, Cell metabolism.
[66] Dudley Lamming,et al. Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity , 2012, Science.
[67] P. Soares,et al. The mTOR Signalling Pathway in Human Cancer , 2012, International journal of molecular sciences.
[68] J. Sarkaria,et al. North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. , 2011, International journal of radiation oncology, biology, physics.
[69] C. Jung,et al. ULK1 inhibits the kinase activity of mTORC1 and cell proliferation , 2011, Autophagy.
[70] P. Houghton,et al. Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin , 2011, Molecular Cancer Therapeutics.
[71] K. Ryan,et al. The multiple roles of autophagy in cancer , 2011, Carcinogenesis.
[72] X. Zhao-Fan,et al. mTOR partly mediates insulin resistance by phosphorylation of insulin receptor substrate-1 on serine(307) residues after burn. , 2011, Burns : journal of the International Society for Burn Injuries.
[73] D. Sabatini,et al. mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.
[74] Philippe P Roux,et al. mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide , 2010, The EMBO journal.
[75] J. Sarkaria,et al. Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks , 2010, Clinical Cancer Research.
[76] Tohru Natsume,et al. Tti1 and Tel2 Are Critical Factors in Mammalian Target of Rapamycin Complex Assembly* , 2010, The Journal of Biological Chemistry.
[77] Chang Hwa Jung,et al. mTOR regulation of autophagy , 2010, FEBS letters.
[78] M. Kastan,et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. , 2010, Immunity.
[79] Robert L Sutherland,et al. PI3K pathway activation in breast cancer is associated with the basal‐like phenotype and cancer‐specific mortality , 2010, International journal of cancer.
[80] L. Partridge,et al. Mechanisms of Life Span Extension by Rapamycin in the Fruit Fly Drosophila melanogaster , 2010, Cell metabolism.
[81] Janet M. Thornton,et al. Ribosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span , 2009, Science.
[82] M. Karsy,et al. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility. , 2009, International journal of oncology.
[83] M. Karsy,et al. Inhibition of mTOR Activates the MAPK Pathway in Glioblastoma Multiforme. , 2009, Cancer genomics & proteomics.
[84] J. Asara,et al. Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1 , 2009, Molecular and Cellular Biology.
[85] Marco Pahor,et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice , 2009, Nature.
[86] A. Salminen,et al. Regulation of the aging process by autophagy. , 2009, Trends in molecular medicine.
[87] J. Blenis,et al. Molecular mechanisms of mTOR-mediated translational control , 2009, Nature Reviews Molecular Cell Biology.
[88] D. Sabatini,et al. An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.
[89] Robbie Loewith,et al. Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 , 2009, PLoS biology.
[90] D. Guertin,et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. , 2009, Cancer cell.
[91] K. Alberti,et al. Diagnosis and Classification of Diabetes Mellitus , 2009, Diabetes Care.
[92] J. Ting,et al. NLRs at the intersection of cell death and immunity , 2008, Nature Reviews Immunology.
[93] S. Horvath,et al. Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma , 2008, PLoS medicine.
[94] D. Sabatini. mTOR and cancer: insights into a complex relationship , 2006, Nature Reviews Cancer.
[95] D. Sabatini,et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.
[96] Matt Kaeberlein,et al. Extension of chronological life span in yeast by decreased TOR pathway signaling. , 2006, Genes & development.
[97] Alexandros Tzatsos,et al. Nutrients Suppress Phosphatidylinositol 3-Kinase/Akt Signaling via Raptor-Dependent mTOR-Mediated Insulin Receptor Substrate 1 Phosphorylation , 2006, Molecular and Cellular Biology.
[98] Matt Kaeberlein,et al. Regulation of Yeast Replicative Life Span by TOR and Sch9 in Response to Nutrients , 2005, Science.
[99] J. Blenis,et al. Analysis of mTOR signaling by the small G‐proteins, Rheb and RhebL1 , 2005, FEBS letters.
[100] Oliver E. Owen. Ketone bodies as a fuel for the brain during starvation , 2005 .
[101] R. Loewith,et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive , 2004, Nature Cell Biology.
[102] Di Chen,et al. The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span , 2004, Development.
[103] T. Golub,et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways , 2004, Nature Medicine.
[104] S. Benzer,et al. Regulation of Lifespan in Drosophila by Modulation of Genes in the TOR Signaling Pathway , 2004, Current Biology.
[105] Tibor Vellai,et al. Genetics: Influence of TOR kinase on lifespan in C. elegans , 2003, Nature.
[106] Andrew G Fraser,et al. Rates of Behavior and Aging Specified by Mitochondrial Function During Development , 2002, Science.
[107] J. Crespo,et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. , 2002, Molecular cell.
[108] D. Sabatini,et al. mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery , 2002, Cell.
[109] J. Avruch,et al. Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action , 2002, Cell.
[110] R. Burcelin,et al. Hypoinsulinaemia, glucose intolerance and diminished β-cell size in S6K1-deficient mice , 2000, Nature.
[111] A. Montag,et al. Proinsulin processing by the subtilisin-related proprotein convertases furin, PC2, and PC3. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[112] Jayson A. Neil,et al. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes. , 2015, Advances in biological regulation.
[113] G. Schmitz,et al. Metformin: An Inhibitor of mTORC1 Signaling , 2014 .
[114] Y. Liu,et al. Changes of plasma fibroblast growth factor-21 (FGF-21) in oral glucose tolerance test and effects of metformin on FGF-21 levels in type 2 diabetes mellitus. , 2013, Endokrynologia Polska.
[115] N. Seidah. The proprotein convertases, 20 years later. , 2011, Methods in molecular biology.